In this report, the Short Bowel Syndrome Therapeutics Market has been segmented by Drug, Route of Administration, Distribution Channel and Geography.

Short Bowel Syndrome Therapeutics Market, Segmentation by Drug

The Short Bowel Syndrome Therapeutics Market has been segmented by Drug into Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog[Teduglutide (Gattex/Revestive)], - Long-acting GLP-2 Analog[Glepaglutide, Apraglutide (FE 203799) and Others], Glutamine, Growth Hormone, Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist, and Others.

Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog [Teduglutide (Gattex/Revestive)]

Short-acting GLP-2 Analog, particularly Teduglutide, dominates the short bowel syndrome therapeutics market, contributing approximately 41% of global revenue in 2022. This GLP-2 analog enhances intestinal absorption and reduces dependence on parenteral nutrition, offering significant clinical benefits for patients with short bowel syndrome.

Glucagon-like Peptide-2 (GLP-2) Analog - Long-acting GLP-2 Analog [Glepaglutide, Apraglutide (FE 203799) and Others]

Long-acting GLP-2 Analogs hold an estimated 29% share of the global short bowel syndrome therapeutics market. These agents offer improved compliance and convenience due to their extended half-life. Ongoing clinical trials and promising results for Glepaglutide and Apraglutide support future growth in this segment.

Glutamine

Glutamine contributes approximately 10% of the short bowel syndrome therapeutics market. This amino acid supports intestinal mucosal healing and enhances nutrient absorption. Its role as a supportive therapy in combination with other treatments supports steady market demand.

Growth Hormone

Growth Hormone holds an estimated 8% share of the short bowel syndrome therapeutics market. It enhances intestinal adaptation and reduces parenteral nutrition dependency. The combination of growth hormone with GLP-2 analogs is gaining traction for improving patient outcomes.

Glucagon-like Peptide-1 (GLP-1) Analog

GLP-1 Analogs account for around 4% of the short bowel syndrome therapeutics market. These agents, though primarily used for diabetes, are being explored for their potential in improving gut motility and nutrient absorption. Ongoing clinical studies support future growth.

Insulin (NTRA 9620)

Insulin (NTRA 9620) holds an estimated 3% share of the short bowel syndrome therapeutics market. This investigational therapy aims to enhance intestinal growth and function. Its development is supported by promising preclinical and clinical data.

TGR5 Agonist

TGR5 Agonists contribute around 2% of the short bowel syndrome therapeutics market. These novel agents aim to modulate bile acid signaling pathways to improve intestinal absorption and reduce parenteral nutrition needs. Ongoing research supports potential future applications.

Others

The "Others" category, including emerging therapies and experimental agents, holds an estimated 3% of the short bowel syndrome therapeutics market. These treatments target unmet needs and offer potential for innovation and future growth.

Short Bowel Syndrome Therapeutics Market, Segmentation by Route of Administration

The Short Bowel Syndrome Therapeutics Market has been segmented by Route of Administration into Injectable and Oral.

Injectable

Injectable therapies dominate the short bowel syndrome therapeutics market, contributing approximately 68% of global revenue in 2022. These include GLP-2 analogs, growth hormone, and insulin-based therapies, which are administered via parenteral routes to ensure targeted delivery and optimal bioavailability. Their proven efficacy and established use drive strong demand in this segment.

Oral

Oral therapies hold an estimated 32% share of the short bowel syndrome therapeutics market. These include glutamine, GLP-1 analogs, and emerging oral agents targeting intestinal adaptation and nutrient absorption. The convenience of oral administration and growing focus on patient-centric therapies support continued growth in this segment.

Short Bowel Syndrome Therapeutics Market, Segmentation by Distribution Channel

The Short Bowel Syndrome Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

Hospital Pharmacies

Hospital Pharmacies dominate the short bowel syndrome therapeutics market, contributing approximately 52% of global revenue in 2022. These outlets ensure timely access to specialized treatments like injectable GLP-2 analogs and growth hormone therapies. The growing use of advanced therapeutics and rising demand for complex care management support sustained demand.

Retail Pharmacies

Retail Pharmacies account for around 34% of the short bowel syndrome therapeutics market. These facilities offer a range of oral medications and nutritional supplements for ongoing management. The increasing shift towards outpatient care and growing patient preference for accessible options drive growth in this segment.

Online Pharmacies

Online Pharmacies hold an estimated 14% share of the short bowel syndrome therapeutics market. The rising trend of digital healthcare platforms and growing demand for home delivery services contribute to this segment’s expansion. Online pharmacies provide convenient access to a wide range of therapeutic products and supportive care options.

Short Bowel Syndrome Therapeutics Market, Segmentation by Geography

In this report, the Short Bowel Syndrome Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Short Bowel Syndrome Therapeutics Market Share (%), by Geographical Region

North America

North America leads the short bowel syndrome therapeutics market, contributing approximately 43% of global revenue in 2022. The region benefits from advanced healthcare infrastructure, strong regulatory frameworks, and the presence of leading market players. The increasing availability of GLP-2 analogs and rising awareness of short bowel syndrome management support robust growth.

Europe

Europe holds around 27% of the short bowel syndrome therapeutics market. Growth in this region is supported by rising clinical research collaborations, a strong focus on innovative therapies, and increasing access to advanced treatment options. Regulatory initiatives promoting rare disease management further fuel expansion.

Asia Pacific

Asia Pacific accounts for an estimated 20% share of the short bowel syndrome therapeutics market. Rapidly improving healthcare access, increasing investments in rare disease treatment, and growing diagnostic capabilities contribute to regional growth. Key contributors include China, Japan, and India.

Middle East and Africa

Middle East and Africa contribute approximately 6% of the global short bowel syndrome therapeutics market. Expanding healthcare infrastructure, rising government initiatives to support rare disease treatment, and collaborations with market leaders enhance growth in this region.

Latin America

Latin America holds around 4% of the short bowel syndrome therapeutics market. The region's growth is supported by increasing awareness of rare disorders, expanding healthcare access, and improving availability of advanced treatments. Regional initiatives to strengthen healthcare systems and raise diagnostic awareness further support expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Short Bowel Syndrome Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence of gastrointestinal disorders globally
• Increasing adoption of parenteral nutrition therapies
• Advancements in biologic drug formulations

• Growing awareness among patients and caregivers - In recent years, there has been a significant increase in awareness among patients and caregivers about short bowel syndrome (SBS), which has become a key driver in the market. With better access to medical information, people are more informed about symptoms, potential complications, and the available treatment options. This growing consciousness has led to a rise in early diagnosis rates and timely intervention, improving patient outcomes.

  The role of patient advocacy groups and online platforms cannot be understated, as they continue to provide essential information, share patient stories, and raise awareness globally. Healthcare campaigns conducted by hospitals, NGOs, and pharma companies are also helping in educating caregivers about long-term nutritional management and post-surgical care.

  The increased awareness has sparked a demand for better treatment access, government reimbursement programs, and insurance coverage for SBS therapies. It is also encouraging participation in clinical trials, boosting research and innovation in this space. With continued focus on education and outreach, the market is expected to expand steadily.

Restraints

• High cost of SBS therapeutic treatments
• Limited awareness in developing regions
• Adverse effects of long-term parenteral use

• Scarcity of pediatric-specific treatment options - One of the major challenges in the SBS therapeutics market is the lack of tailored treatments for pediatric patients. Children with SBS have unique nutritional and physiological needs, which often cannot be addressed adequately by therapies designed for adults. This gap limits the effectiveness of standard treatments and often leads to complications or prolonged dependency on parenteral nutrition.

  Most drug formulations are not optimized for pediatric metabolism, making it harder for healthcare providers to prescribe safe and effective doses for children. Furthermore, ethical and logistical challenges in conducting clinical trials involving children further delay the development of specialized therapies. The absence of robust pediatric data also makes regulatory approval more difficult.

  Due to the scarcity of pediatric-specific options, many young patients experience increased risks of infections, growth delays, and liver complications from prolonged parenteral nutrition. The current gap in pediatric innovation not only restricts treatment effectiveness but also places emotional and financial burdens on families and caregivers.

Opportunities

• Ongoing R&D in regenerative medicine
• Potential of gene therapies for SBS
• Partnerships for novel drug development

• Expanding clinical trials in emerging economies - The SBS therapeutics market is experiencing a surge in opportunities due to the expansion of clinical trials in emerging economies. Countries in Asia-Pacific, Latin America, and parts of Eastern Europe are increasingly being targeted for research initiatives due to their large patient populations, lower operational costs, and improving healthcare infrastructure. This geographic diversification is helping to generate real-world evidence across diverse demographics.

  Governments in these regions are also offering support through fast-track approvals, trial site subsidies, and improved ethical review frameworks. Pharmaceutical companies and research institutions are capitalizing on these developments to expedite the discovery of more effective and affordable therapies.

  The growing involvement of local hospitals and universities in SBS-related trials is fostering stronger partnerships between public and private sectors. This collaboration not only helps in developing region-specific solutions but also increases the overall market accessibility and patient outreach. As data from emerging markets continues to grow, it will likely play a crucial role in shaping regulatory strategies and commercialization efforts.

Key players in Short Bowel Syndrome Therapeutics Market include:

• Takeda Pharmaceutical Company Limited
• AbbVie Inc
• Novartis International AG
• Pfizer Inc
• Shire
• Fresenius Kabi AG
• Nestlé Health Science
• Emmaus Life Sciences, Inc
• Zealand Pharma A/S
• Nutrinia Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis